Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27944719 | 0.83 | SORT1 (0.33) | — | |
| SCHEMBL4365987 | 0.82 | — | — | |
| SCHEMBL87312 | 0.81 | CYP3A4 (0.32) | — | |
| SCHEMBL3304997 | 0.80 | — | — | |
| Bromide SCHEMBL1045354 | 0.79 | CYP3A4 (0.31) | — | |
| Hydrochloric Acid SCHEMBL572769 | 0.79 | CYP3A4 (0.31) | — | |
| Iodide SCHEMBL2341578 | 0.79 | CYP3A4 (0.31) | — | |
| Bromide SCHEMBL28977680 | 0.78 | — | — | |
| Iodide SCHEMBL4363781 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL4367848 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721900-B1 | NOVEL IMIDAZOLIUM COMPOUND | KANTO KAGAKU (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-7517999-B2 | needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070191612-A1 | Needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | HIROYUKI OHNO (JP) | 2007-08-16 | — | — | US | disclosed |
| CN-1922152-A | Novel imidazolium compound | KANTO KAGAKU (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1721900-A1 | NOVEL IMIDAZOLIUM COMPOUND | Kanto Kagaku Kabushiki Kaisha (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191612-A1 | Needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity, electrolytes; 1-butyl-3-allylimidazolium bromide | SLC26A3, KCNJ11, SLC26A4 | TSHR 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.